Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA “Approvable” Letter For Gestiva Recommends Additional Animal Study

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, Adeza’s long-acting form of progesterone would be the first FDA-approved treatment for preterm birth.

You may also be interested in...



KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval

NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.

KV Purchases Hologic Premature Birth Prevention Candidate; Sale Contingent On FDA Approval

NDA approval is expected in late 2008 for Gestiva, which has been under review since April 2006.

Columbia Labs' Prochieve Could Address $150 Million To $300 Million Preterm Birth Market

Firm anticipates sNDA approval for progesterone vaginal gel product in recurrent preterm birth as early as 2008.

Related Content

Topics

UsernamePublicRestriction

Register

OM004634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel